Evidence map›Paper›PMID 32040761›Full record

ArticleRheumatology international2020

Individual therapeutic DAS28-d

Michaela Koehm, Matthew J McIntosh, Michael W Hofmann, Varghese Abraham, Cem Gabay, Ernest H Choy, Arthur Kavanaugh, Harald Burkhardt, Frank Behrens

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michaela KoehmRheumatology and Fraunhofer IME, Branch for Translational Medicine and Pharmacology (TMP), Goethe University, Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Germany. Michaela.Koehm@ime.fraunhofer.de.
Matthew J McIntoshGenentech, South San Francisco, CA, USA.
Michael W HofmannChugai Pharma Europe Ltd., Frankfurt am Main, Germany.
Varghese AbrahamGenentech, South San Francisco, CA, USA.
Cem GabayGeneva University Hospital, Geneva, Switzerland.
Ernest H ChoySection of Rheumatology, CREATE Centre, Cardiff University School of Medicine, Cardiff, UK.
Arthur KavanaughUniversity of California, San Diego, San Diego, CA, USA.
Harald BurkhardtRheumatology and Fraunhofer IME, Branch for Translational Medicine and Pharmacology (TMP), Goethe University, Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Germany.
Frank BehrensRheumatology and Fraunhofer IME, Branch for Translational Medicine and Pharmacology (TMP), Goethe University, Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Assessment of individual therapeutic responses provides valuable information concerning treatment benefits in individual patients. We evaluated individual therapeutic responses as determined by the Disease Activity Score-28 joints critical difference for improvement (DAS28-d

Indexed as

Patient Reported Outcome MeasuresSeverity of Illness IndexAntibodies, Monoclonal, HumanizedAntirheumatic AgentsArthritis, RheumatoidBlood SedimentationHumansObservational Studies as TopicRandomized Controlled Trials as TopicRetrospective StudiesTreatment OutcomeTumor Necrosis Factor InhibitorsAntibodies, Monoclonal, HumanizedAntirheumatic AgentstocilizumabTumor Necrosis Factor InhibitorsAnti-rheumatic agentsPatient outcome assessmentRheumatoid arthritisTocilizumabTreatment effectiveness

Identifiers

PMID32040761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.